Immunotherapy exhibits durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary
resistance to immunotherapy are multifaceted, deriving not only from
tumor intrinsic factors, but also from the complex interplay between
cancer and its microenvironment. We have designed drug screening
assays which reflect the resistance mechanism of immunotherapy and
screened pDOS library to identify hit compounds to overcome the
resistance to immunotherapy.

SBP-101, a prodrug form, is a representative compound at GLP-tox study. The active metabolite binds to HMGB1 and controls DAMP. In B16F10 syngeneic study, SB-101 exhibited significant anti-cancer efficacy as a stand-alone therapy as well as combination therapy with anti PD1 antibody.

Since the advent of SARS-Cov-2 in 2019, researchers have tried to
develop vaccine and therapies. The recent successful development
of several different types of vaccines reduced mortality dramatically.
However, the spread of viral infection persists due to the rapid mutation
of spike protein and the need of new oral therapeutics is still huge.
We rationally designed screening system to identify hit compounds to
inhibit the viral entry (the interaction between hACE2 and the Spike
protein),to inhibit the process of viral proteins (protease) or the viral replication inside host cells (RNA-dependent RNA Polymerase).
This program is at early discovery stage.

Non-Alcoholic SteatoHepatitis
Idiopathic Pulmonary Fibrosis
Heart Failure with Preserved Ejection Fraction

One of the most important discoveries of the past two decades is that
the inflammation is involved in a wide variety of mental and physical
health problems, with more than 50% of all deaths being attributable to inflammation-related diseases such as ischemic heart disease, stroke, cancer, d iabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease (NAFLD) and autoimmune and neurodegenerative conditions. Both innate and adaptive immune systems are involved in differently in each disease. We designed screening system to identify hit compounds to control innate immune system as well as adaptive immune system such as inflammatory cell infiltration, antigen presentation, coreceptor expression and so on. We are vigorously testing the library to identify drug candidate compounds. One identified candidate compound reduced DAMP-mediated cytokine secretion from macrophages and inflammation in tissues. This candidate compound efficiently prevented fibrosis in in vivo NASH model and preserved heart function in in vivo Drug-induced heart failure model.